A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia

Br J Haematol. 2020 Aug;190(3):e169-e173. doi: 10.1111/bjh.16804. Epub 2020 Jun 9.
No abstract available

Keywords: acute myeloid leukaemia; chemotherapy; clinical studies; selinexor.

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Combined Modality Therapy
  • Cytarabine / administration & dosage
  • Drug Resistance, Neoplasm
  • Female
  • Follow-Up Studies
  • Gastrointestinal Diseases / chemically induced
  • Hematologic Diseases / chemically induced
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Hematopoietic Stem Cell Transplantation / mortality
  • Humans
  • Hydrazines / administration & dosage
  • Idarubicin / administration & dosage
  • Kaplan-Meier Estimate
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / therapy
  • Male
  • Middle Aged
  • Progression-Free Survival
  • Recurrence
  • Salvage Therapy*
  • Triazoles / administration & dosage

Substances

  • Hydrazines
  • Triazoles
  • Cytarabine
  • selinexor
  • Idarubicin